175 related articles for article (PubMed ID: 27418444)
1. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
2. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
[TBL] [Abstract][Full Text] [Related]
3. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
4. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
[TBL] [Abstract][Full Text] [Related]
5. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
[TBL] [Abstract][Full Text] [Related]
6. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
[TBL] [Abstract][Full Text] [Related]
7. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
Gyamfi C; Horton AL; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Meis PJ; Spong CY; Dombrowski M; Sibai B; Varner MW; Iams JD; Mercer BM; Carpenter MW; Lo J; Ramin SM; O'Sullivan MJ; Miodovnik M; Conway D;
Am J Obstet Gynecol; 2009 Oct; 201(4):392.e1-5. PubMed ID: 19716543
[TBL] [Abstract][Full Text] [Related]
8. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
;
Am J Obstet Gynecol; 2023 Jul; 229(1):B2-B6. PubMed ID: 37061078
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
[TBL] [Abstract][Full Text] [Related]
10. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
Szychowski JM; Berghella V; Owen J; Hankins G; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
J Matern Fetal Neonatal Med; 2012 Dec; 25(12):2686-9. PubMed ID: 22889234
[TBL] [Abstract][Full Text] [Related]
11. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Saha PT; Mbewe FM; Phiri WM; Peterson M; Muyangwa D; Sindano N; Mwape H; Smithmyer ME; Kasaro MP; Rouse DJ; Goldenberg RL; Chomba E; Stringer JSA
Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
[TBL] [Abstract][Full Text] [Related]
12. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
Alizadeh F; Mahmoudinia M; Mirteimoori M; Pourali L; Niroumand S
BMC Pregnancy Childbirth; 2022 Mar; 22(1):167. PubMed ID: 35232423
[TBL] [Abstract][Full Text] [Related]
13. Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis.
Conde-Agudelo A; Romero R
Am J Obstet Gynecol; 2022 Sep; 227(3):440-461.e2. PubMed ID: 35460628
[TBL] [Abstract][Full Text] [Related]
14. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341
[TBL] [Abstract][Full Text] [Related]
15. Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study.
Mazza GR; Komatsu E; Ponzio M; Bai C; Cortessis VK; Sasso EB
BMC Pregnancy Childbirth; 2024 Apr; 24(1):252. PubMed ID: 38589796
[TBL] [Abstract][Full Text] [Related]
16. Comparison the efficacy of vaginal progesterone
Alavi A; Ranjbar A; Atighpoor F; Zare S
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7438-7444. PubMed ID: 34470137
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
Megli CJ; Hauspurg A; Venkataramanan R; Caritis SN
Am J Perinatol; 2023 Oct; 40(14):1585-1589. PubMed ID: 34784615
[TBL] [Abstract][Full Text] [Related]
19. Concurrent progestogen and cerclage to reduce preterm birth: a multicenter international retrospective cohort.
Tolosa JE; Boelig RC; Bell J; Martínez-Baladejo M; Stoltzfus J; Mateus J; Quiñones JN; Galeano-Herrera S; Pereira L; Burwick R; López-Torres L; Valencia C; Berghella V;
Am J Obstet Gynecol MFM; 2024 Mar; ():101351. PubMed ID: 38513806
[TBL] [Abstract][Full Text] [Related]
20. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
Tsur A; Leonard SA; Kan P; Datoc IA; Girsen AI; Shaw GM; Stevenson DK; El-Sayed YY; Druzin ML; Blumenfeld YJ
Am J Perinatol; 2023 Aug; 40(11):1158-1162. PubMed ID: 37100422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
